--- title: "Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of \"Moderate Buy\" by Brokerages" description: "Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received a consensus rating of \"Moderate Buy\" from seven research firms. The ratings include one sell, one hold, four buy, and one strong buy. The ave" type: "news" locale: "en" url: "https://longbridge.com/en/news/276528649.md" published_at: "2026-02-22T06:46:07.000Z" --- # Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages > Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received a consensus rating of "Moderate Buy" from seven research firms. The ratings include one sell, one hold, four buy, and one strong buy. The average price target is $13.80, with Chardan Capital setting a target of $20.00. The stock opened at $3.92, with a market cap of $221.34 million. Institutional investors own 53.20% of the company, which focuses on developing therapies for inflammatory and oncologic diseases. Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.80. Get **Orchestra BioMed** alerts: OBIO has been the subject of several analyst reports. Chardan Capital reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a "buy" rating for the company. Finally, Barclays lifted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Friday, January 9th. **Check Out Our Latest Research Report on OBIO** ## Orchestra BioMed Stock Performance NASDAQ:OBIO opened at $3.92 on Friday. The firm has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.66. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The firm has a market cap of $221.34 million, a PE ratio of -2.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. ## Institutional Investors Weigh In On Orchestra BioMed Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Orchestra BioMed during the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new position in Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. increased its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $847,000. Finally, Marshall Wace LLP bought a new stake in Orchestra BioMed in the 4th quarter valued at $712,000. Institutional investors and hedge funds own 53.20% of the company's stock. ## Orchestra BioMed Company Profile (Get Free Report) Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis. Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs. ## See Also - Five stocks we like better than Orchestra BioMed - ~$1.5T SpaceX IPO: Pre-IPO Opportunity - America’s 1776 happening again - What a Former CIA Agent Knows About the Coming Collapse - How a Family Trust May Be Able To Help Preserve Your Wealth - This makes me furious *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Orchestra BioMed Right Now? Before you consider Orchestra BioMed, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list. While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [OBIO.US - Orchestra BioMed](https://longbridge.com/en/quote/OBIO.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Terns Pharmaceuticals, Inc.（納斯達克股票代碼：TERN）被券商給予 “適度買入” 的平均評級 | Terns Pharmaceuticals, Inc.（納斯達克代碼：TERN）獲得了十三位分析師的 “適度買入” 平均評級。一位分析師將其評為賣出，十一位評為買入，一位評為強力買入。平均目標價為 58.11 美元。最近的報告顯示，來自各個 | [Link](https://longbridge.com/en/news/276308345.md) | | 阿伯丁集團有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 價值 1416 萬美元的股票 | 阿伯丁集團 plc 在第三季度將其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，價值 1416 萬美元。其他機構投資者也調整了他們的持股。分析師對 CRNX 的評 | [Link](https://longbridge.com/en/news/276426109.md) | | 隨着第二階段 DMD 項目的推進，Satellos Bioscience 正在吸引投資者 | Satellos Bioscience（多倫多證券交易所代碼：MSCL）計劃在二月下旬和三月初參加幾場醫療保健會議，以吸引投資者，因為其 DMD 候選藥物 SAT-3247 正在進行第二階段臨牀試驗。該公司旨在提高知名度並吸引資本，強調該藥 | [Link](https://longbridge.com/en/news/276358401.md) | | 安進在花旗峯會上詳細介紹了其在腫瘤研發方面的推進、IMDELLTRA 的擴展以及 LUMAKRAS 的最新進展 | 安進的高管在花旗的虛擬腫瘤領導峯會上介紹了公司的腫瘤研發優先事項和關鍵項目的最新進展。他們強調了針對難治性腫瘤的差異化療法，重點關注 T 細胞連接劑和精準小分子。更新內容包括 IMDELLTRA 在小細胞肺癌中的推出、正在進行的三期臨牀試驗 | [Link](https://longbridge.com/en/news/276288691.md) | | Abivax 報告稱 Obefazimod 在克羅恩病中具有抗纖維化潛力，並能迅速緩解症狀 | Abivax SA (ABVX) 在第 21 屆 ECCO 年會上展示了 obefazimod 的有希望的研究結果，突顯其在克羅恩病中的抗纖維化潛力。該療法表現出良好的安全性，並迅速緩解症狀，臨牀療效在第 1 周就顯著可見。生物標誌物數據表 | [Link](https://longbridge.com/en/news/276513475.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.